Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04721366 · ClinicalTrials.gov registry record
A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease
A clinical trial, sponsored by Takeda.
- Completed
- Registry status
- 11
- Enrollment target
NCT04721366 is a clinical trial that has completed, run by Takeda. The registered enrollment target is 11 participants.
The verdict
NCT04721366 has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- 11 participants
- Enrollment target
Study Summary
The main aim of this study is to learn if velaglucerase alfa (VPRIV) improves growth and symptoms in participants up to 5 years of age with Gaucher disease. Symptoms will be checked with blood tests. This study is about collecting data available in the participant's medical record as well as data from each participant's ongoing treatment. No study medicines will be provided to participants in this study. The study sponsor will not be involved in how participants are treated but will provide instructions on how the clinics will record what happens during the study. When the participants start the study, they will visit the study clinic every 6 months after their first visit.
Interventions
- OTHER Standard of Care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2021-01-08 |
| Est. Completion | 2023-04-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04721366
The ClinicalTrials.gov registry entry for NCT04721366 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Standard of Care is the first listed.
NCT04721366 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04721366 about?
NCT04721366 is a clinical study titled "A Study of Velaglucerase Alfa (VPRIV) Given as Standard Patient Care in Young Children With Gaucher Disease". The main aim of this study is to learn if velaglucerase alfa (VPRIV) improves growth and symptoms in participants up to 5 years of age with Gaucher disease. Symptoms will be checked with blood tests. This study is about collecting data available in the participant's medical record as well as data f...
What is the current status of trial NCT04721366?
This trial is currently completed. The enrollment target is 11 participants. The study started on 2021-01-08. Estimated completion is 2023-04-17.
What interventions are being tested in trial NCT04721366?
The interventions under investigation include: Standard of Care (OTHER).
Who is sponsoring clinical trial NCT04721366?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.